

(Alliance News) - Hutchmed (China) Ltd on Friday said it has completed the rolling submission of a new drug application for its fruquintinib cancer dr...


(Alliance News) - Hutchmed China Ltd on Tuesday said it closed a license agreement with a subsidiary of Tokyo-based drug maker Takeda Pharmaceutical C...


(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and Wednesday and...


(Alliance News) - Hutchmed (China) Ltd expects a sharp rise in revenue from its oncology and immunology-focused arm, as the biopharmaceutical firm loo...


(Sharecast News) - Hutchmed China announced the completion of patient enrollment in a phase two registration trial of 'amdizalisib' on Monday, for the...


(Alliance News) - Hutchmed (China) Ltd on Monday said that it has completed patient enrolment for the Phase Two registration trial of amdizalisib, its...


(Alliance News) - Hutchmed (China) Ltd on Monday said it has signed an licensing agreement with Takeda Pharmaceutical Co Ltd for the Japanese company ...